NCT06029296进行中（未招募）早期 1 期
Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder
适应症
干预措施
试验速览
- 阶段
- 早期 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Kynurenic Acid
研究概览
简要总结
This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages 21-65
- •Meet DSM-5 diagnostic criteria for AUD of any severity (Mild, Moderate, or Severe)
排除标准
- •Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders
- •Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants
- •Self-reported daily use of opioids (including prescribed)
- •Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
- •If female: pregnant, nursing, or with reproductive potential who refuses to use reliable methods of birth control throughout the study
- •Any autoimmune disorder, inflammatory disorder, or medical condition that may interfere with safe study participation and/or study aims (e.g., any cardiac, renal, or liver disease, uncontrolled hypertension, or diabetes)
- •Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year
- •Currently on prescription medication that contraindicates use of diclofenac, including but not necessarily limited to: oral corticosteroids, anticoagulants, lithium, warfarin, aspirin (daily use), methotrexate, cyclosporine, ACE-inhibitors, and diuretics like furosemide and thiazides
- •Previously known hypersensitivity, including gastroenteritis, asthma, and allergic-type reactions, to any NSAID and/or aspirin
- •Current daily use of any NSAID or regular pattern of near daily use within the past three months, regular use of a prebiotic or probiotic supplement and/or any antibiotic, prebiotic, or probiotic use within the last month
- •Any lifetime history of ulcer disease, gastritis, gastroenteritis, or gastrointestinal bleeding
- •Current or recent (within 3 months) participation in a clinical trial involving medication administration
- •Currently in treatment, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment for AUD
- •Current (last 12 months) DSM-5 diagnosis of SUD for any psychoactive substances other than alcohol and nicotine
- •Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders
- •AST and ALT > four times the upper limit of the normal range, or albumin, GFR, BUN, or creatinine 15% > the upper limit of the normal range
- •Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12
- •Has below a 6th grade reading level
- •Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms
- •Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity
研究组 & 干预措施
Diclofenac
Active Comparator
Participants will take a single 100mg dose of diclofenac.
干预措施: Diclofenac (Drug)
Placebo
Placebo Comparator
Participants will take a single dose of placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Kynurenic Acid
时间窗: 0-, 60-, 120-, 180-, and 240-minutes after pill administration
Serum levels of Kynurenic Acid
次要结局
未报告次要终点
研究者
Daniel Roche
Assistant Professor
University of Maryland, Baltimore
研究点 (1)
Loading locations...
相似试验
招募中
2 期
The Antimicrobial Potential of Diclofenac Sodium as an Intracanal MedicamentEndodontic DiseasePulp Disease, DentalIntracanal MedicationNCT06207253British University In Egypt48
已完成
4 期
The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee OsteoarthritisKnee OsteoarthritisNCT01383954Brigham and Women's Hospital52
已完成
3 期
Diclofenac Potassium With Lidocaine Cream in Reducing Pain During HSGPain Relief With HSGNCT02709590Assiut University140
终止
2 期
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM PatientsType 2 DiabetesNCT00622089DiObex150
Unknown
2 期
Diclofenac Potassium on IANB Efficacy in Symptomatic Irreversible PulpitisIrreversible PulpitisNCT03163420Cairo University68